NCT01874522View on ClinicalTrials.gov

Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

November 30, 2015

Conditions
Advanced Solid Tumors (Excluding Breast Cancer)
Interventions
DRUG

TAS-102 tablets

"Crossover bioavailability part: 60 mg/dose, orally, up to 2 single doses separated by 1-week washout.~Extension part: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met."

DRUG

TAS-102 oral solution

60 mg/dose, orally, up to 2 single doses separated by 1-week washout

Trial Locations (1)

85258

Scottsdale Healthcare, Scottsdale

All Listed Sponsors
lead

Taiho Oncology, Inc.

INDUSTRY

NCT01874522 - Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI | Biotech Hunter | Biotech Hunter